热门资讯> 正文

非侵入性骨生长刺激器上CMS更换后Orthofix激增

2026-07-06 22:59

Orthofix Medical (OFIX) is up 16% on Monday after CMS on July 1 decided to reverse a final order that reclassified non-invasive bone growth stimulators.
TD Cowen's Matthew Blackman, who rates the stock a hold, said that "OFIX now expects rates to return to prior levels."
The "reversal by CMS of what had seemed to be a strange decision at the time makes sense, though a further assessment of reimbursement for bone growth stimulation products at some point in the future certainly remains a possibility," added Barrington's Michael Petusky, who has an outperform rating on Orthofix.

More on Orthofix Medical

Orthofix Medical Inc. (OFIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Orthofix Medical Inc. 2026 Q1 - Results - Earnings Call Presentation
Orthofix Medical Inc. (OFIX) Q1 2026 Earnings Call Transcript
Orthofix Medical rises on CMS reversal of non-invasive bone growth stimulators
Orthofix lowers outlook on Medicare changes to bone growth stimulators

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。